---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-104920"
form_type: "8-K"
ticker: "BCLI"
cik: "0001137883"
company_name: "BRAINSTORM CELL THERAPEUTICS INC."
filed_at: "2024-10-01T23:59:59+00:00"
generated_at: "2026-05-30T23:01:47.912447+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Brainstorm Cell Therapeutics effects 1-for-15 reverse stock split to meet Nasdaq bid price requirement

## Summary
- Reverse stock split at 1:15 ratio effective 11:59 p.m. ET on September 30, 2024.
- Trading on split-adjusted basis began October 1, 2024; new CUSIP 10501E300.
- Authorized shares unchanged at 250 million; fractional shares paid in cash based on closing price.
- Reverse split also applies to warrants, options, and RSUs with proportionate adjustments.
- Split intended to increase per share bid price above $1.00 to satisfy Nasdaq continued listing.

## SEC filing metadata
- accession: 0001104659-24-104920
- form_type: 8-K
- ticker: BCLI
- cik: 0001137883
- company_name: BRAINSTORM CELL THERAPEUTICS INC.
- filed_at: 2024-10-01T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.01, 5.03, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/0001104659-24-104920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1137883/000110465924104920/tm2425273d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-104920
- JSON: https://secwatch.observer/filing/0001104659-24-104920.json
- Plain text: https://secwatch.observer/filing/0001104659-24-104920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.